EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Immunomodulatory Precision: A Narrative Review Exploring the Critical Role of Immune Checkpoint Inhibitors in Cancer Treatment

Junyu Qiu iD, Zilin Cheng, Zheng Jiang, Luhan Gan, Zixuan Zhang, Zhenzhen Xie iD

International Journal of Molecular Sciences · 17.05.2024 · 25 (10) · 5490

DOI: 10.3390/ijms25105490 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 17.05.2024. Verfasst von Junyu Qiu und 5 weiteren Autor:innen. Beteiligte Einrichtung: College of Basic Medical, Nanchang University, Nanchang 330006, China. Hauptthemen laut MEDLINE: Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 226 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

An immune checkpoint is a signaling pathway that regulates the recognition of antigens by T-cell receptors (TCRs) during an immune response. These checkpoints play a pivotal role in suppressing excessive immune responses and maintaining immune homeostasis against viral or microbial infections. There are several FDA-approved immune checkpoint inhibitors (ICIs), including ipilimumab, pembrolizumab, and avelumab. These ICIs target cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), and programmed death ligand 1 (PD-L1). Furthermore, ongoing efforts are focused on developing new ICIs with emerging potential. In comparison to conventional treatments, ICIs offer the advantages of reduced side effects and durable responses. There is growing interest in the potential of combining different ICIs with chemotherapy, radiation therapy, or targeted therapies. This article comprehensively reviews the classification, mechanism of action, application, and combination strategies of ICIs in various cancers and discusses their current limitations. Our objective is to contribute to the future development of more effective anticancer drugs targeting immune checkpoints.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsImmune Checkpoint InhibitorsHumansAnimalsCTLA-4 AntigenImmunotherapyProgrammed Cell Death 1 ReceptorImmunomodulation

Stichwörter der Autor:innen

anti-cancer drugscancer treatmentcombination immunotherapiesimmune checkpoint inhibitors (ICIs)immune response

Substanzen

Immune Checkpoint InhibitorsCTLA-4 AntigenProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • College of Basic Medical, Nanchang University, Nanchang 330006, China.
  • Queen Mary School, Medical Department, Nanchang University, Nanchang 330031, China.
  • Huan Kui School, Medical Department, Nanchang University, Nanchang 330031, China.

ORCID-Profile: Junyu Qiu, Zhenzhen Xie

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Qiu, J., Cheng, Z., Jiang, Z., Gan, L., Zhang, Z., & Xie, Z. (2024). Immunomodulatory Precision: A Narrative Review Exploring the Critical Role of Immune Checkpoint Inhibitors in Cancer Treatment. International Journal of Molecular Sciences, 25(10), 5490. https://doi.org/10.3390/ijms25105490

Vancouver

Qiu J, Cheng Z, Jiang Z, Gan L, Zhang Z, Xie Z. Immunomodulatory Precision: A Narrative Review Exploring the Critical Role of Immune Checkpoint Inhibitors in Cancer Treatment. International Journal of Molecular Sciences. 2024;25(10):5490. doi:10.3390/ijms25105490

BibTeX
@article{Qiu2024,
  author = {Qiu, Junyu and Cheng, Zilin and Jiang, Zheng and Gan, Luhan and Zhang, Zixuan and Xie, Zhenzhen},
  title = {Immunomodulatory Precision: A Narrative Review Exploring the Critical Role of Immune Checkpoint Inhibitors in Cancer Treatment},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {10},
  pages = {5490},
  doi = {10.3390/ijms25105490}
}
Kostenlos starten →